Tags

Type your tag names separated by a space and hit enter

Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study.
Clin Appl Thromb Hemost. 2006 Apr; 12(2):205-12.CA

Abstract

The aim of this study was to investigate the clinical efficacy of oral Pycnogenol (Horphag Research Ltd., UK) in patients with severe chronic venous insufficiency (CVI) in comparison to the combination of diosmin and hesperidin (Daflon, Servier, France). A group of 86 patients with severe chronic venous insufficiency (CVI), venous hypertension, ankle swelling) and previous history of venous ulcerations received either oral Pycnogenol (capsules) 150 mg or 300 mg daily for 8 weeks or Daflon, 1,000 mg/day. All patients completed the study without dropouts. At the end of the study, microcirculatory results indicated: a progressive decrease of skin flux at rest (RF); a significant decrease in capillary filtration (RAS); an improvement in the symptomatic venous score (ASLS); a reduction in edema; a significant improvement (increase) in pO(2) and a decrease in pCO(2) in the Pycnogenol group. A significant level of improvement was reached after 4 weeks of treatment in most patients (p < .05) of the Pycnogenol group while clinical improvement was significant only in 6 subjects in the Daflon group. The positive effects of treatment with Pycnogenol after 8 weeks were significantly larger in comparison with the Daflon group. In conclusion, this study confirms the fast clinical efficacy of Pycnogenol in patients with chronic venous insufficiency and venous microangiopathy and its superiority-considering the evaluated parameters-to the combination of diosmin and hesperidin.

Authors+Show Affiliations

Irvine2 Vascular Lab and Physiology, Department of Biomedical Sciences, G D'Annunzio, Chieti-Pescara University, San Valentino Vascular Screening Project, Faculty of Motory Sciences, L'Aquila University, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16708123

Citation

Cesarone, M R., et al. "Comparison of Pycnogenol and Daflon in Treating Chronic Venous Insufficiency: a Prospective, Controlled Study." Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, vol. 12, no. 2, 2006, pp. 205-12.
Cesarone MR, Belcaro G, Rohdewald P, et al. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb Hemost. 2006;12(2):205-12.
Cesarone, M. R., Belcaro, G., Rohdewald, P., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Acerbi, G., Cacchio, M., Di Renzo, A., Hosoi, M., Stuard, S., & Corsi, M. (2006). Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 12(2), 205-12.
Cesarone MR, et al. Comparison of Pycnogenol and Daflon in Treating Chronic Venous Insufficiency: a Prospective, Controlled Study. Clin Appl Thromb Hemost. 2006;12(2):205-12. PubMed PMID: 16708123.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. AU - Cesarone,M R, AU - Belcaro,G, AU - Rohdewald,P, AU - Pellegrini,L, AU - Ledda,A, AU - Vinciguerra,G, AU - Ricci,A, AU - Gizzi,G, AU - Ippolito,E, AU - Fano,F, AU - Dugall,M, AU - Acerbi,G, AU - Cacchio,M, AU - Di Renzo,A, AU - Hosoi,M, AU - Stuard,S, AU - Corsi,M, PY - 2006/5/19/pubmed PY - 2006/8/29/medline PY - 2006/5/19/entrez SP - 205 EP - 12 JF - Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis JO - Clin Appl Thromb Hemost VL - 12 IS - 2 N2 - The aim of this study was to investigate the clinical efficacy of oral Pycnogenol (Horphag Research Ltd., UK) in patients with severe chronic venous insufficiency (CVI) in comparison to the combination of diosmin and hesperidin (Daflon, Servier, France). A group of 86 patients with severe chronic venous insufficiency (CVI), venous hypertension, ankle swelling) and previous history of venous ulcerations received either oral Pycnogenol (capsules) 150 mg or 300 mg daily for 8 weeks or Daflon, 1,000 mg/day. All patients completed the study without dropouts. At the end of the study, microcirculatory results indicated: a progressive decrease of skin flux at rest (RF); a significant decrease in capillary filtration (RAS); an improvement in the symptomatic venous score (ASLS); a reduction in edema; a significant improvement (increase) in pO(2) and a decrease in pCO(2) in the Pycnogenol group. A significant level of improvement was reached after 4 weeks of treatment in most patients (p < .05) of the Pycnogenol group while clinical improvement was significant only in 6 subjects in the Daflon group. The positive effects of treatment with Pycnogenol after 8 weeks were significantly larger in comparison with the Daflon group. In conclusion, this study confirms the fast clinical efficacy of Pycnogenol in patients with chronic venous insufficiency and venous microangiopathy and its superiority-considering the evaluated parameters-to the combination of diosmin and hesperidin. SN - 1076-0296 UR - https://www.unboundmedicine.com/medline/citation/16708123/full_citation L2 - https://journals.sagepub.com/doi/10.1177/107602960601200209?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -